Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Tunisia

Coordination and Support Action · Running

VISION From Insightful Science to Innovative Health: Strengthening Translational Capacity and Talent Interoperability in Vaccine and Biologic Research & innovation

Coordinator
Institut Pasteur De Tunis, Tunisia
Runs
1 September 2023 to 31 August 2027
Status
Running
EU funding
€2.7m
Total cost
€2.7m
Partners
11 organisations in 7 countries
Type
Coordination and Support Action
Grant agreement
101120507

What the project is doing

In the project's own words, from its summary on CORDIS.

Following the COVID-19 pandemic, biologicals and vaccines became regarded as salient pillars for disease prevention and control. However, strengthening preparedness for and response to health emergencies request more commitment and intersectoral cooperation between academia and industry to set up efficient strategies against diseases, whether through surveillance, detection, diagnosis, prevention, or treatment. VISION (Vaccine & bIologics reSearch & innovatION) intends to implement an intensive intersectoral and bidirectional knowledge/know-how transfer programs in order to reinforce vaccine and biologics development capacities with manufacturing, upscaling, or delivery capabilities among a consortium with Institut Pasteur de Tunis (Tunisia), Darnitsa (Ukraine), Torlak Institute (Serbia) and Connect’innov (Tunisia) as academic (AC) & non-academic (NA) widening members; Institut Pasteur (France) and Center for Genomic Regulation (Spain) as academic research non widening (NW) organizations, Ciloa (France), ACTG-CRO (France), M4Health (Germany) and iBET (Portugal) as NW&NA partners.

VISION comes as a critical lever for R&I ecosystem feeding post-pandemic needs and matches the WHO mRNA Transfer initiative aiming to enhance widening production capacities and help achieving a comprehensive health coverage towards Sustainable Development Goals. VISION will in fine streamline the discovery, testing and production of biologics and vaccine candidates including mRNA-based technologies. VISION's main objectives are threefold: (i) endow Widening Talents with advanced knowledge and skills in Vaccine and Biologics Development, (ii) promote more impactful collaboration through training and mobility between AC and NA sectors towards an efficient high-performance translational R&I environment with an Open Science pillar, and (iii) ambition to make widening members a regional flagship for excellence in innovative research with increased biobusiness and entrepreneurship capacity and openness to the socio-economic sector.

Topics

Who is involved

OrganisationCityCountryRole
Institut Pasteur De TunisTunisTunisiaCoordinator
Quantoom BiosciencesNivellesBelgiumParticipant
management4health AGFrankfurt Am MainGermanyParticipant
Fundacio Centre De Regulacio GenomicaBarcelonaSpainParticipant
CiloaMontpellierFranceParticipant
Institut PasteurParisFranceParticipant
Millipore SASMolsheimFranceParticipant
Institut Za Virusologiju Vakcine Iserume TorlakBeogradSerbiaParticipant
Actg-CroTunisTunisiaParticipant
World Bio Consulting Tunisia BranchLa MarsaTunisiaParticipant
Pharmaceutical Firm DarnitsaKyivUkraineParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI